Proton-Pump Inhibitors (PPIs) are commonly prescribed medications indicated for the
treatment of various acid-related disorders including duodenal/gastric ulcers, erosive
oesophagitis and Helicobacter Pylori eradication
[1]
,
[2]
. PPIs are frequently used without appropriate indication in older adults and are
associated with numerous adverse effects including bone loss, fractures, community
acquired pneumonia and chronic kidney disease
[1]
,
[2]
. Strikingly, several studies have also reported a greater risk of dementia in those
receiving a long-term PPI
[3]
,
[4]
. By contrast, in rigorous studies in both the UK and Finland, no association between
PPI use and dementia occurrence was observed
[5]
,
[6]
. Thus, it appears that early alarming reports of dementia risk associated with long-term
PPI use may have been overstated.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Adverse effects of proton-pump inhibitor use in older adults: a review of the evidence.Ther Adv Drug Saf. 2017; 8: 273-297
- Adverse effects associated with proton pump inhibitors.JAMA Intern Med. 2016; 176: 172-174
- Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis.JAMA Neurol. 2016; 73: 410-416https://doi.org/10.1001/jamaneurol.2015.4791
- Risk of dementia in elderly patients with the use of proton pump inhibitors.Eur Arch Psychiatry Clin Neurosci. 2015; 265: 419-428https://doi.org/10.1007/s00406-014-0554-0
- Proton pump inhibitor use and risk of developing alzheimer's disease or vascular dementia: a case-control analysis.Drug Saf. 2018; 41: 1387-1396https://doi.org/10.1007/s40264-018-0704-9
- No association between proton pump inhibitor use and risk of Alzheimer's disease.Am J Gastroenterol. 2017; 112: 1802-1808https://doi.org/10.1038/ajg.2017.196
- Nilvadipine in mild to moderate Alzheimer disease: a randomised controlled trial.PLoS Med. 2018; 15e1002660https://doi.org/10.1371/journal.pmed.1002660
Lewis JR, Barre D, Zhu K, Ivey KL, Lim EEM, Hughes J, Prince RL. Long-term proton-pump inhibitor therapy and falls and fractures in elderly women: a prospective cohort study. J Bone Miner ResDoi.org/10.1002/jbmr.2279.
- Screening for delirium using family caregivers: convergent validity of the family confusion assessment method and interviewer-rated confusion assessment method.J Am Geriatr Soc. 2012; 60: 2121-2126https://doi.org/10.1111/j.1432-5415.2012.04200.x
- The association between gastric acid inhibitors and delirium in geriatric inpatients: implications for clinical practice and research.Clin Interv Aging. 2016; 11: 797-799
Article info
Publication history
Published online: May 07, 2020
Accepted:
April 3,
2020
Received:
March 1,
2020
Identification
Copyright
© 2020 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
